2.105

2.68% 0.055

Allogene Therapeutics Inc (ALLO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$2.05

Aprire:

$2.06

Volume 24 ore:

1.31M

Relative Volume:

0.64

Capitalizzazione di mercato:

$435.07M

Reddito:

$95,000

Utile/perdita netta:

$-327.27M

Rapporto P/E:

-0.8592

EPS:

-2.45

Flusso di cassa netto:

$-239.25M

1 W Prestazione:

-14.43%

1M Prestazione:

-24.82%

6M Prestazione:

-21.75%

1 anno Prestazione:

-25.35%

Intervallo 1D:

$2.005

$2.14

Intervallo di 1 settimana:

$1.99

$2.52

Portata 52W:

$1.99

$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Nome

Allogene Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(650) 457-2700

Indirizzo

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Dipendente

361

Cinguettio

@AllogeneTx

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

ALLO's Discussions on Twitter

Confronta ALLO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALLO	2.105	435.07M	95,000	-327.27M	-239.25M	-2.45
VRTX	450.91	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	749.43	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	589.59	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.94	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.93	24.89B	3.30B	-501.07M	1.03B	11.54

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-05	Downgrade	Guggenheim	Buy → Neutral
2024-01-05	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Iniziato	Citigroup	Buy
2023-06-26	Ripresa	Oppenheimer	Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-01-24	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-12-12	Downgrade	BofA Securities	Buy → Underperform
2022-08-10	Downgrade	Raymond James	Outperform → Mkt Perform
2022-07-15	Aggiornamento	Goldman	Neutral → Buy
2022-06-03	Iniziato	Robert W. Baird	Neutral
2022-02-28	Reiterato	B. Riley Securities	Buy
2021-10-20	Iniziato	Cowen	Outperform
2021-10-08	Downgrade	Goldman	Buy → Neutral
2021-10-08	Downgrade	Stifel	Buy → Hold
2021-09-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-21	Ripresa	Jefferies	Buy
2021-05-20	Aggiornamento	Truist	Hold → Buy
2021-05-14	Iniziato	B. Riley Securities	Buy
2021-01-26	Aggiornamento	Stifel	Hold → Buy
2020-12-10	Ripresa	H.C. Wainwright	Buy
2020-11-24	Iniziato	BofA Securities	Buy
2020-10-23	Iniziato	RBC Capital Mkts	Outperform
2020-06-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-29	Reiterato	H.C. Wainwright	Buy
2020-05-19	Aggiornamento	ROTH Capital	Neutral → Buy
2020-05-15	Aggiornamento	Guggenheim	Neutral → Buy
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-05-14	Downgrade	SunTrust	Buy → Hold
2020-04-13	Iniziato	SunTrust	Buy
2020-03-13	Iniziato	H.C. Wainwright	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-24	Iniziato	Berenberg	Hold
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-11-04	Iniziato	Canaccord Genuity	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-06-05	Iniziato	ROTH Capital	Neutral
2019-05-31	Iniziato	Guggenheim	Neutral
2019-05-23	Iniziato	Stifel	Hold
2019-03-29	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

Nov 20, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewswire

Nov 19, 2024

Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire

Nov 18, 2024

Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan

Nov 18, 2024

Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com

Nov 18, 2024

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat

Nov 18, 2024

Nov 15, 2024

Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia

Nov 15, 2024

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™

Nov 15, 2024

Nov 14, 2024

Allogene halts enrollment in leukemia trial - Investing.com

Nov 14, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat

Nov 14, 2024

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace

Nov 14, 2024

Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat

Nov 14, 2024

Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK

Nov 14, 2024

Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024

Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India

Nov 12, 2024

Nov 10, 2024

Allogene Therapeutics Q3 2024 Earnings Preview - MSN

Nov 10, 2024

Nov 09, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Earnings call: Allogene Therapeutics reports on CAR T therapy progress - Investing.com

Nov 08, 2024

Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 08, 2024